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ABSTRACT 
 
 Introduction - Bibersteinia trehalosi has been associated with respiratory disease in 
ruminants particularly in wild and domestic sheep. Recently, there has been an increased 
interest in B. trehalosi isolates obtained from diagnostic samples from bovine respiratory 
disease cases. This study evaluated the role of B. trehalosi in the bovine respiratory disease 
complex using an intra-tracheal inoculation model in calves.  This study also evaluated the 
potential of haptoglobin-matrix metalloproteinase 9 (Hp-MMP 9) serum concentrations as 
a useful diagnostic tool in calves affected with B. trehalosi and M. haemolytica associated 
respiratory disease. 
 Materials and Methods – Thirty-five cross-bred dairy steers were inoculated 
intra-tracheally with either leukotoxin negative or leukotoxin positive B. trehalosi, 
Mannheimia haemolytica, a combination of leukotoxin negative B. trehalosi and M. 
haemolytica, or negative control.  Physical examinations were conducted and serum samples 
were collected throughout the study.  Calves were euthanized and necropsies performed on 
day 10 of the study. 
 Results - No significant differences were found between the groups of calves 
challenged with B. trehalosi alone or in conjunction with M. haemolytica and the negative 
control calves with respect to percent lung involvement, rectal temperature, respiratory or 
depression score, or serum Hp or Hp-MMP 9 concentration in this study.  M. haemolytica 
inoculated calves, but not B. trehalosi inoculated calves had increased lung involvement 
compared to control calves.  B. trehalosi was only cultured once from the lungs of 
inoculated calves at necropsy.  Increases in serum Hp and Hp-MMP 9 concentrations for 
the M. haemolytica group became significantly different from other groups on day 7.  The 
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leukotoxin positive B. trehalosi group demonstrated increased serum Hp-MMP 9 
concentrations on days 3-10 compared to pre-inoculation concentrations. 
Conclusions - Based on these findings B. trehalosi may not be a primary pathogen 
of respiratory disease in cattle. Culture of B. trehalosi from diagnostic submissions should 
not be immediately identified as a primary cause of respiratory disease.  Serum Hp-MMP 9 
concentration is a useful diagnostic tool for detecting early pulmonary inflammation in 
calves challenged with B. trehalosi and M. haemolytica.  Serum Hp-MMP 9 may also be a 
useful tool in detecting subclinical pulmonary inflammation in challenged calves. 
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CHAPTER 1 
INTRODUCTION 
 
 The bovine respiratory disease complex (BRDC) is bronchopneumonia of 
polymicrobial and multifactorial etiology.  This complex is a major cause of morbidity and 
mortality among cattle, particularly cattle in confined feeding operations [1, 2]. Diagnosis 
with BRDC is associated with subsequent negative health, welfare and performance.  
Because of the cost of treatment and the subsequent performance loss, BRDC is of major 
economic importance to the North American beef industry [3-5].  Many viral and bacterial 
pathogens as well as environmental conditions have been identified as components of or 
sufficient causes of BRDC [6].  Historically, in the United States Bibersteinia trehalosi has 
not been included as a pathogenic cause of BRDC for several reasons.  Until 2012, very 
few case reports had been published associating Bibersteinia trehalosi with disease in 
cattle.  The great majority of the reports were published in Europe.  Bibersteinia 
trehalosi’s potential role in BRDC in North America was not given much consideration [7-
11].  Cortese et al. published a series of case reports in 2012 describing peracute to fatal 
pneumonia in cattle caused by Bibersteinia trehalosi in the United States [12].  The 
purpose of this thesis was to determine whether or not Bibersteinia trehalosi should be 
included as a component of BRDC.  
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Thesis Organization 
 Chapter 2 is a literature review of the Bibersteinia trehalosi organism, its disease 
presentations in sheep and cattle, and its comparison to the Mannhaemia haemolytica 
organism. 
 Chapter 3 is a manuscript that has been published in BioMed Central Veterinary 
Research.  It describes a pilot study that was designed to evaluate the pathogenicity of B. 
trehalosi in respiratory disease among calves using field strains of B. trehalosi. The study 
design and results were used to determine if Bibersteinia trehalosi is capable of causing 
respiratory disease in dairy cross calves in an experimental setting [13]. 
 Chapter 4 is a manuscript that has been submitted to BioMed Central Veterinary 
Research (submitted 11 July 2014).  This manuscript assesses and describes the diagnostic 
potential of haptoglobin-matrix metalloproteinase 9 (Hp-MMP 9) complexes as an 
antemortem assessment of respiratory disease in cattle infected with Bibersteinia trehalosi 
or Mannhaemia haemolytica [14]. 
 Chapter 5 summarizes conclusions from research described in chapters 3 and 4.  
Suggestions for directions of future research related to Bibersteinia trehalosi in cattle are 
also discussed. 
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CHAPTER 2 
 LITERATURE REVIEW 
Bibersteinia trehalosi 
 
Background 
Bibersteinia trehalosi is and has historically been an important pathogen of sheep, 
primarily as the cause of septicemia in 4 -10 month old lambs.  It has also been associated 
with pneumonia [1, 2].  Reports have been published in which the organism was isolated 
from other ruminant species including cattle, goats, and bison [2-5].  Bibersteinia trehalosi 
is currently the most common member of the Pasteurellaceae family to be cultured from 
the tonsils of commercially reared American bison [1].   
 
Bacterial Characteristics 
 Bibersteinia trehalosi is a small, non-motile, gram negative rod that exhibits slight 
pleomorphism.  The organism can be seen occurring singly, in pairs, or in short chains 
depending on growth stage [1, 6]. 
When grown on bovine blood agar, colonies are round, regular, greyish or 
yellowish in color with a smooth, shiny surface that graduates to semi-transparent at the 
periphery.  Some isolates exhibit a weak margin of β-hemolysis [1, 6].  All 14 bovine 
isolates used in a classification study failed to show hemolytic activity [1].  Colonies are 
about 2 millimeters in diameter after 24 hours of aerobic incubation at 37°C.  Growth 
occurs between 25 and 40°C, with an optimum temperature of 37°C.  Isolates have been 
demonstrated to be CAMP-positive (Christie Atkins Munch-Petersen) and have weak 
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growth on MacConkey agar.  Cultures produce both oxidase and phosphatase, but not 
catalase, urease, or indole.  Acid is produced without gas from glucose, cellobiose, 
raffinose, aesculin, amygdalin, arbutin, gentibiose, dulcitol, galactose, mannose, trehalose, 
and salicin, but not from glycerol or myo-inositol [1, 6].  The organisms’ ability to ferment 
trehalose has historically been the characteristic differentiating Bibersteinia trehalosi from 
other members of the Pasteurellaceae family. 
Young log phase cultures show good encapsulation of the organisms.  Older 
cultures show little cell associated capsular material.  The predominantly smooth 
lipopolysaccharide (LPS) of Bibersteinia trehalosi has been shown to have a negative 
effect on lung function in sheep following direct instillation into the lung.  Initially a 
marked decrease in circulating leukocyte count was observed followed by mild 
leukocytosis.  Lung lavage showed increased cell counts with most being neutrophils.  LPS 
invoked inflammation, edema, hyperemia, and hemorrhage in the lung.  These effects are 
similar to those reported for experimental acute pneumonia and are more marked for 
smooth LPS than rough LPS.  LPS complexes with the sheep’s lung surfactant potentiating 
its damaging effect [6].   
Some strains of Bibersteinia trehalosi have been demonstrated to produce 
leukotoxin.  Acutely growing rather than stationary phase organisms are required for 
leukotoxin production.  The leukotoxin is specific for alveolar macrophages and circulating 
blood lymphocytes, neutrophils, and cultured blood mononuclear cells from cattle, sheep, 
and goats.  It has little or no effect on cells from swine, horses, or humans.  Leukotoxin 
significantly reduces the production of oxidative metabolites.  The alveolar macrophages 
from calves appear to be more susceptible to the effects of the leukotoxin than those of 
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adult cattle.  Neutrophils also appear to be more sensitive than either alveolar or mammary 
macrophages [6].  
The ability of Pasteurellaceae isolates to produce beta hemolysis on culture media 
has been extensively studied.  Attempts have been made to correlate this ability to 
leukotoxin production and pathogenicity.  Conflicting results have been produced from 
studies [7-9] designed to determine whether beta hemolysis should be used as an index for 
pathogenicity in adult sheep, in lambs, or not at all.  In the Miller et al. 2013 study 
described below only 9 of the 16 Bibersteinia trehalosi strains were leukotoxin positive on 
PCR.  None of the clade strains were leukotoxin positive despite reportedly showing beta 
hemolysis in culture [9].  The ability of Bibersteinia trehalosi strains to produce leukotoxin 
rather than beta hemolysis in culture has been determined to be the most important 
virulence factor of the organism [10].  
 
Taxonomic Classification 
Literature describing Bibersteinia trehalosi is complicated by the constantly 
evolving nomenclature of the organism as it undergoes increasing differentiation from 
other members of the Pasteurellaceae family.  The description of the bacteria now known 
as Bibersteinia trehalosi was first published in 1921 by F.S. Jones with an original name of 
Bacillus bovisepticus group I [11].  In 1932 Newsom and Cross proposed a name change 
for the bacteria to Pasteurella haemolytica [12]. 
G.R. Smith proposed in 1959 that the Pasteurella haemolytica complex be divided 
into two biotypes, A and T, based on the ability of the different strains to ferment 
arabinose and trehalose respectively.  He described the differences between the two strains 
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based on cultural and epidemiologic differentiation in sheep.  He observed that the colonial 
morphology of type A strains appeared to be even and greyish with a central thickening.  
Type A was associated with enzootic pneumonia.  Compared to type A strains, colonies of 
type T strains were larger when cultured and were associated with septicemia in lambs 
[13].   
Ernst Biberstein was responsible for much of the early work done that characterized 
the organism, created the serotyping scheme, and indicated the unique nature of the taxon 
based on DNA-DNA relatedness studies [1].  Biberstein et al. subdivided the A and T 
biotypes in to serotypes in 1960 using an indirect hemagglutination assay (IHA).  This 
assay relied on differences in capsular polysaccharides between strains.  Biberstein 
identified 16 serotypes with 12 belonging to the biotype A group and 4 belonging to the 
biotype T group [14].  The four serotypes belonging to the biotype T group were T3, T4, 
T10, and T15.  These four serotypes show 98.7% similarity in a phylogenetic analysis 
based on 16S rRNA gene sequences [1].   
Due to the inability of several isolates to be serotyped due to cross-agglutination 
reactions or nonreactivity to existing typing sera, a system of classification into biogroups 
and biotypes was developed by Bisgaard and Mutters in 1986 using 21 phenotypic 
characteristics [15].  The T biotype of Pasteurella haemolytica was officially recognized as 
a separate species from the A biotype and renamed Pasteurella trehalosi [16].  Jaworski et 
al. used the phenotypic classification system in 1998 to reclassify isolates of Pasteurella 
haemolytica biotypes A and T, Pasteurella trehalosi, and Pasteurella multocida in order to 
identify lineages with the highest pathogenicity.  The previously identified serotypes 3, 4, 
10, and 15 of Pasteurella trehalosi were all regrouped as biotype 2.  This biogroup 
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predominated in wildlife species and also accounted for 21% of the Pasteurella isolates 
from domestic sheep, but were not present in the isolates from cattle.  Fifty- six percent 
(259/464) of the Pasteurella isolates were classified as Pasteurella trehalosi in wildlife 
species.  The Pasteurella trehalosi isolates all belonged to either biogroup 2 or a new 
group, biogroup 4.  The biogroups were differentiated by isolates from biogroup 2 being 
positive for β-glucosidase activity while isolates from biogroup 4 were negative for β-
glucosidase activity.  Twenty-one percent (27/126) of the Pasteurella isolates from 
domestic ruminants were classified as Pasteurella trehalosi with 74% (20/27) belonging to 
biogroup 2.  The remainder were classified as biogroup 4 or variants of either biogroup 
[17]. 
Blackall et al. demonstrated in 2007 that there was 62% or less DNA-DNA 
relatedness between Pasteurella trehalosi and the other members of the Pasteurellaceae 
family.  Based on this difference, he proposed the bacteria name be changed to 
Bibersteinia trehalosi after Ernst L. Biberstein [1].   
 Miller et al. used 16S rRNA sequencing and leukotoxin A sequencing via PCR 
assay to clarify phylogenetic and epidemiologic relationships among Pasteurellaceae 
isolated from bighorn sheep in 2013 [9].  When this method was compared to the 
metabolism based method described by Jaworski et al. [17], only 16 of 25 trehalose-
fermenting Bibersteinia trehalosi isolates were determined to be Bibersteinia trehalosi.  
The other 9 isolates formed a Bibersteinia trehalosi-like clade that was divergent from the 
reference strains of Bibersteinia trehalosi.  Based on these findings, it has been determined 
that traditional metabolism based methods of identifying members of the Pasteurellacea 
family lack sufficient accuracy and resolution for reliably discerning bacterial causes of 
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respiratory disease in bighorn sheep.  Thus, if using metabolism based identification 
methods, strong consideration should be given to augmentation with molecular techniques 
for phylogenetic analysis [9]. 
 
Treatment and Prevention  
According to the Iowa State University Diagnostic Lab susceptibility profile for 
bovine pathogens from 2010-2012, Bibersteinia trehalosi is most susceptible to treatment 
with drugs from the ceftiofur (88%), florfenicol (75%), and potentiated sulfa (75%) classes 
of antibiotics [18].  The presence of antimicrobial resistance genes in Bibersteinia trehalosi 
was first reported in 2006 in an isolate obtained from the lung of a calf with clinical signs 
of respiratory disease in France through the RESAPATH network.  FloR-mediated 
resistance to chloramphenicol and florfenicol were associated with a plasmid which also 
carried functionally active genes for resistance to sulfonamides.  The plasmid was 
composed almost exclusively of segments previously associated with other plasmids, 
transposons, or insertion sequences found in other members of the Pasteurellaceae family.  
This finding provides evidence of gene flow between Pasteurellaceae [2].   
No vaccine is commercially available in the USA against Bibersteinia trehalosi.  
Several companies offer customized autogenous bacterins.  However, evidence that 
substantiates vaccine effectiveness is lacking.  Confer et al. demonstrated that serum 
antibody levels to LPS in vaccinated calves did not appear to correlate with protection in 
1986 and 1987 studies [19, 20]. 
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Bibersteinia trehalosi in Domestic and Wild Sheep 
 When Bibersteinia trehalosi was classified in the Pasteurella haemolytica complex 
it was reported that the organism was commonly carried in the nasopharynx and tonsils of 
apparently healthy domestic sheep.  By 9 weeks of age 90% of tonsilar isolates from lambs 
were one of the T biotypes.  The rate of nasal carriers of the T biotype of Pasteurella 
haemolytica was observed to peak in late autumn, coinciding with increased incidence of 
disease.  No evidence was established indicating that increased carrier rate was the cause 
of disease. Pasteurella haemolytica type T was primarily associated with septicemia in 
older lambs and less commonly with sheep atypical pneumonia [21].   
  
Septicemia 
Septicemia typically occurred in spring born lambs during the months of September 
through December with a mortality rate between 2.5 and 3.2%.  In general, reported 
clinical signs included sudden death, dullness, pyrexia, recumbency, frothy discharge of 
the mouth, dyspnea, and prostration leading to death within 6-8 hours.  A higher mortality 
rate was seen on day one of outbreaks before decreasing over the next few days.  Typical 
gross post mortem features of the disease included lambs in good body condition with 
frank blood exiting through the nostrils.  Hemorrhages were noted on the pleura, 
epicardium, endocardium, heart valves, visceral peritoneum, mesenteric lymph nodes, and 
spleen.  The trachea and bronchi were congested with blood stained froth.  The lungs were 
congested, heavy, and bluish in color, with widespread focal hemorrhages.  Clear, blood 
tinged exudate was observed in both pleural and peritoneal cavities.  Fibrinous pericarditis, 
focal hemorrhagic hepatic necrosis, edematous lymph nodes, and blotchy kidneys were 
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also observed.  Histologically alveolar edema, capillary congestion, and varying amounts 
of hemorrhage could be seen in lung tissue with colonies of bacteria forming thrombi in 
capillaries [21].  Bibersteinia trehalosi is still reported to cause systemic septicemia.  A 
case was reported by Szeredi et al. in 2008 of systemic Bibersteinia trehalosi being 
diagnosed with an immunohistochemical method using rabbit hyperimmune serum raised 
against Bibersteinia trehalosi serotype 3 from a weaned lamb that died suddenly.  Large 
numbers of Bibersteinia trehalosi were identified extracellularly in necrotic foci of the 
liver, tonsil, and nasal mucosa.  Large numbers of the organism were also identified in the 
cytoplasm of inflammatory cells in alveoli and bronchioli.  Low numbers of the organism 
were observed in the spleen, mediastinal lymph nodes, kidney and ileum.  No organisms 
were observed in the heart muscle or brain [22]. 
 
Respiratory Disease 
Pasteurella haemolytica biotype T was associated with about 10% of atypical 
pneumonia affecting sheep from 2-12 months of age.  Atypical pneumonia was described 
as a proliferative, exudative pneumonia of the anterior and dependent parts of the lungs by 
Gilmour and Brotherston in 1963 [23].  It was defined pathologically by Stamp and Nisbet 
in 1963, who also proposed the name atypical pneumonia [24].  Other names for the 
disease have been apical, lobar, enzootic, chronic enzootic, and chronic non-progressive 
pneumonia.  Clinical signs included coughing, dyspnea, hyperpnea exacerbated by 
exercise, dullness, and mucopurulent nasal discharge.  Grossly the lungs appeared with 
either raised, firmly consolidated grey/pink areas or with sunken, dull red areas of 
atelectasis.  Enlarged bronchial lymph nodes could also be observed post mortem.  
13 
 
 
Pasteurella haemolytica could reportedly be cultured from most early cases of atypical 
pneumonia, but was gradually eliminated from the lesions over a period of 8-11 weeks 
[21]. 
 Bibersteinia trehalosi has also been associated with respiratory disease in adult 
domestic sheep with clinical signs of sudden, severe illness, inappetence, pyrexia, toxemia, 
and tachypnea consistent with endotoxemia.  This presentation is similar to other gram 
negative infections.  Differentiation is often not attempted due to positive response to IV 
treatment with oxytetracycline and NSAID therapy [25].   
 In a case study by Gonzalez et al. in 2013 describing Mannheimia haemolytica and 
Bibersteinia trehalosi serotypes isolated from lambs with ovine respiratory complex in 
Spain it was determined that the T4 serotype was most associated with a lack of 
consolidated lesions in lungs.  Serotypes of a T3-T15 group were most often associated 
with lung consolidation.  The researchers concluded that the T4 serotype had a greater 
degree of pathogenicity and was more likely to be associated with the septicemic form of 
disease [26].   
Prevalence rate of Bibersteinia trehalosi in domestic sheep in the United States has 
been reported as 18% [27] and 6.7% in the highlands of Ethiopia [28].  The Gonzalez case 
study provided evidence of regional differences in the frequency of serotype isolation.  The 
T4 serotype was the most common serotype isolated in the study in Spain, Donachie et al. 
[29] most frequently isolated the T15 serotype in Scotland, and Villard et al. [30] most 
frequently isolated the T3 serotype in France. 
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Bighorn Sheep 
 Large scale die offs of bighorn sheep populations in the western United States from 
pneumonia have recently been reported.  Much attention has been given to investigate the 
etiologic agent(s) that may be responsible for the epidemics and have been focused on 
Bibersteinia trehalosi, Mannhaemia haemolytica, or viral causes [31].   
Pasteurella trehalosi was shown to be isolated more frequently from healthy 
bighorn sheep than healthy domestic sheep.  It was isolated at 63% (81/129) and 60% 
(27/45) in two geographically separate populations of bighorn sheep in the western United 
States [27].  It was only isolated in 18% of domestic sheep in areas geographically similar 
to the bighorn herds.  Bibersteinia trehalosi has also been isolated from pneumonic 
bighorn sheep [31] at a higher rate than the isolation of Mannhaemia haemolytica [10, 32].  
The majority of the studies show that the isolation of Bibersteinia trehalosi is not 
correlated to health status, in that it is isolated at a similar rate from the nasopharynx and 
lungs in both apparently healthy and diseased sheep [8].  Most isolates of Bibersteinia 
trehalosi in healthy bighorn sheep are non-hemolytic and leukotoxin negative [10, 27, 32].   
While Bibersteinia trehalosi was frequently isolated in studies of pneumonia in 
bighorn sheep, prior to 2012 it was assumed that it was a secondary pathogen and required 
other contributing factors to cause respiratory disease.  These included: sheep exposure to 
parainfluenza-3 virus, bovine respiratory syncytial virus, Mycoplasma ovipneumoniae, 
transport stress, harsh weather conditions, or other Pasteurellaceae from domestic 
ruminants [8, 31-33].  In one study, single doses of two different antibiotics were 
administered to bighorn sheep prior to translocation in an attempt to decrease the incidence 
of pneumonia due to transportation stress.  The administration of antibiotics was 
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unsuccessful in eliminating Mannhaemia haemolytica and Bibersteinia trehalosi from the 
oropharyngeal cavity of the bighorn sheep and the effect on the incidence of pneumonia 
from transportation stress was undetermined [33]. 
 In 2013 Dassanayake et al. demonstrated that leukotoxin positive Bibersteinia 
trehalosi caused severe and fatal pneumonia in bighorn sheep.  Leukotoxin negative 
Bibersteinia trehalosi did not cause clinical pneumonia, death, or lung lesions in bighorn 
sheep.  Further studies by the same group demonstrated that wild type and leukotoxin 
negative mutants of both Mannhaemia haemolytica and Bibersteinia trehalosi do not cause 
fatal pneumonia in bighorn sheep, suggesting that leukotoxin is the most important 
virulence factor of these organisms [10].  Tomassini et al. demonstrated that neutrophils 
derived from bighorn sheep appear to be more susceptible to leukotoxin that those from 
domestic sheep [27].   
 
Bibersteinia trehalosi in Cattle 
 Bibersteinia trehalosi has been isolated from both healthy and diseased cattle.  The 
organism is carried on nasal, conjunctival, and nasopharyngeal mucosa in healthy cattle 
[34, 35].  Conflicting reports exist about the prevalence of Bibersteinia trehalosi in the 
nasopharynx of healthy cattle.  Some reports describe the organism as a ubiquitous 
commensal organism [36, 37].  Others report that the organism is not readily isolated from 
healthy, unstressed cattle [38].  Most published reports on Bibersteinia trehalosi in cattle 
originate from Europe.  Very little is published about Bibersteinia trehalosi in cattle in the 
United States.  All of the cattle field isolates that Blackall et al. [1] used for the 
reclassification of Pasteurella trehalosi as Bibersteinia trehalosi were from Europe.  Three 
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of the isolates were from granulomas, one isolate was from a joint, and nine isolates were 
from lung tissue.  No indication of disease status of the animals from which the isolates 
were obtained was provided in the study.  None of the bovine isolates in the study 
demonstrated hemolytic ability.  These finding are consistent with other studies that report 
when Bibersteinia trehalosi is isolated from cattle in the United Kingdom the isolates are 
often non-hemolytic [39]. 
 
Respiratory Disease 
 Bibersteinia trehalosi is infrequently identified as a respiratory pathogen in cattle.  
Isolates that are found in diseased animals are usually associated with bronchopneumonia 
[39].  Early reports of pathogenic Bibersteinia trehalosi in cattle are from Europe.  Wray 
and Thompson [40] isolated Pasteurella haemolytica T3 in one instance from a calf with 
pneumonic lungs on post mortem.  Allan et al. [34] cultured Pasteurella haemolytica T10 
on 4 occasions from cattle involved in a respiratory disease outbreak on two separate 
farms.  One isolate was from a yearling bull at the time of slaughter.  Another isolate was 
from a 6 month old calf that died of pneumonia.  The other two isolates were from sick 4 
month old calves.  Isolation of the organism was reportedly associated with proliferative 
bronchiolitis, alveolitis, and focal exudative fibrinous pneumonia, no site of isolation was 
given.  Ball et al. [41] isolated Pasteurella trehalosi from various tissues and fluids in 27 
cattle including lung, brain, nasal swab, milk, vaginal swab, peritoneal swab, mesenteric 
lymph node, feces and small intestine.  Seven isolates were from the serotype T4, 12 
isolates from the serotype T10, and 8 isolates from the T15 serotype.  Only three of the 
cattle that the isolates originated from were exhibiting signs of pneumonia.  Initial isolates 
17 
 
 
of Bibersteinia trehalosi associated with pneumonia in cattle originated in the northwest 
part of the United Kingdom in 2003, but have since spread through the rest of the country 
[35].  In 2009 Confer reported that Bibersteinia trehalosi associated pneumonia in young 
dairy calves had been described, but not documented in refereed literature [36].  In 2012 
Cortese et al. published a series of case reports of peracute to fatal pneumonia in cattle 
caused by Bibersteinia trehalosi in the United States.  The cases occurred in a group of 
mid lactation dairy cows, a group of feedlot bulls and steers, and a group of dairy calves.  
In all cases approximately 10% of the group was affected by respiratory disease that often 
resulted in death.  On necropsy 50-75% of the lungs of each animal were affected, often 
with fibrinous bronchopneumonia.  Affected animals were treated with a variety of 
antimicrobials labeled for use in bovine respiratory disease, but very little positive 
response to treatment was observed.  Bibersteinia trehalosi was isolated either alone or 
with other bacterial respiratory pathogens such as Pasteurella multocida and Mycoplasma 
bovis.  No viruses were usually detected in the reported cases.  BVD was detected with 
PCR in only one calf.  The researchers concluded that cross protection was observed 
within the groups when cattle were vaccinated with a Mannhaemia haemolytica vaccine 
containing leukotoxoid and cell wall antigen [42]. 
   Clinical signs associated with Bibersteinia trehalosi in cattle include coughing, 
tachypnea, nasal discharge, pyrexia, malaise, lethargy, recumbency, wasting, poor body 
condition, and sudden death.  Gross lesions that can be observed on post mortem 
examination include: purulent consolidating emphysematous pneumonia with fibrinous 
pleurisy, bronchial lymph node enlargement, pericarditis, necrotic laryngitis, and 
petechiation of lungs and subcutaneous tissues.  Histologic examination typically 
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demonstrates fibrinopurulent bronchopneumonia and necrotizing fibrinous 
bronchointerstitial pneumonia.  Bibersteinia trehalosi can be isolated most commonly from 
the center of consolidated lung tissue.  All ages of cattle appear to be susceptible with an 
increased prevalence of disease in cattle under 12 months old.  The number of cases peaks 
from October through the winter until about March.  Disease is seen more often in housed 
cattle.  Bibersteinia trehalosi is usually not found with a viral co-infection, but bacterial 
co-infection with other respiratory pathogens is not uncommon [35]. 
 
Other Disease Presentations 
 Although the majority of Bibersteinia trehalosi isolates associated with disease 
originate from pneumonic lung tissue, the organism can also be found in liver, spleen, and 
other tissues [35].  One report from the Scottish Agricultural Collage described a systemic 
infection of a 7 month old calf with Bibersteinia trehalosi that died rapidly [39].  Another 
case report from the UK describes a gravid 9 year old Limousin crossbred cow with a 
nursing calf that was found dead on pasture with no signs of illness on the day prior to 
death.  The cow was in fair body condition.  On post mortem examination fibrinous 
peritonitis and severe focal irregular hemorrhagic lesions on the liver with fibrinous 
exudate on the surface were observed.  A hematoma and hemorrhagic lesions were seen on 
the gallbladder with thickening and calcification of the bile ducts.  The spleen was swollen.  
Fibrinous serositis was observed in the cranial lung lobes and pericardial sac.  A few small 
areas of consolidation were noted on the lungs below the area of pleurisy.  Bibersteinia 
trehalosi was cultured from the liver, pleura, and spleen.  A fluorescent antibody test 
showed positive staining for Clostridium novyi and Clostridium chauveoi.  On histologic 
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evaluation acute necrotizing and hemorrhagic hepatitis was associated with sparse 
degenerate leukocytes, venous thrombosis, and large numbers of gram negative 
coccobacilli in thrombi and sinusoids.  Clostridial organisms were not associated with 
lesions indicating that they were likely post mortem invaders.  Coccobacilli were also 
found on the capsular surface of the liver and within gallbladder and lung lesions [39]. 
 Spagnoli et al. [43] reported a case of a 3 year old Texas longhorn steer with a long 
history of weight loss and progressive swelling of soft tissues of the jaw and neck.  The 
steer was euthanized due to a poor prognosis.  Necropsy findings included multifocal to 
coalescing dermal and subcutaneous pyogranulomas surrounded by fibrous tissue.  
Submandibular and retropharyngeal lymph nodes were enlarged and 5-10% of the 
cranioventral aspect of both lungs was consolidated and dark red.  The pyogranulomas 
contained aggregates of gram negative coccobacilli that were recovered in pure culture and 
determined by molecular methods to be Bibersteinia trehalosi.  This was the first reported 
case of subcutaneous botryomycosis due to Bibersteinia trehalosi. 
 
Comparison of Bibersteinia trehalosi to Mannheimia haemolytica 
 Historically Bibersteinia trehalosi and Mannheimia haemolytica were both 
classified in the Pasteurella haemolytica complex.  The organisms were first differentiated 
from each other based on the ability of Bibersteinia trehalosi to ferment trehalose within 2 
days, but not arabinose until at least day 10; whereas Mannhaemia haemolytica ferments 
arabinose within 7 days, but does not ferment trehalose within 10 days.  Subsequently 
Bibersteinia trehalosi was designated as Pasteurella haemolytica type T and Mannhaemia 
haemolytica was designated Pasteurella haemolytica type A [13].   
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 The two types of Pasteurella haemolytica were further differentiated by clinical 
presentation in diseased animals.  Pasteurella haemolytica type A was most commonly 
associated with pneumonia in cattle [38].  It was also associated with enzootic pneumonia 
in sheep.  Pasteurella haemolytica type T was most commonly associated with septicemic 
disease in 6-12 month old lambs [13]. 
 Differences between the two organisms in colonial morphology were reported 
when the colonies were examined by transmitted light after 18-24 hours.  Pasteurella 
haemolytica type A colonies were described as even, grayish in color, and sometimes 
having a small clearly demarcated central thickening.  Pasteurella haemolytica type T 
colonies were described as larger, up to 2 mm in diameter, with dark brownish centers and 
color fading toward the periphery [13].   
 Differences were also described at a cellular level.  Pasteurella haemolytica type A 
was noted to have rough lipopolysaccharides while type T had smooth 
lipopolysaccharides.  Neuraminidase was produced by most type A strains but not by type 
T strains.  Neuraminidase removes terminal sialic acid residue from salivary glycoproteins 
resulting in a loss of viscosity and adhesiveness.  This can potentially cause a reduction in 
the protective function of the epithelial mucous in that it becomes less able to entrap and 
remove invading microorganisms [6].  It was noted that type A strains were more sensitive 
to tetracycline and penicillin as penicillin failed completely to inhibit growth of the type T 
strains [6, 13].  Most recently, it has been reported that Bibersteinia trehalosi strains are 
more stable when compared to Mannhaemia haemolytica strains that have a higher degree 
of plasticity when analyzed with pulse field gel electrophoresis [44]. 
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Organism Interaction 
 Due to differences observed between the Bibersteinia trehalosi and Mannhaemia 
haemolytica strains in clinical disease presentation and post mortem recovery rates in 
various ruminant species, Dassanayake et al. studied the interaction between the two 
organisms in vitro and in vivo.  Mannhaemia haemolytica had been shown to consistently 
cause pneumonia in bighorn sheep in experimental studies, but Bibersteinia trehalosi, 
which had not been consistently proven to cause pneumonia in bighorn sheep, was isolated 
more frequently from pneumonic lung tissue.  When grown separately Bibersteinia 
trehalosi had a doubling time of about 14 minutes.  Mannhaemia haemolytica had a 
doubling time of about 27 minutes.  In addition to a faster growth rate, Bibersteinia 
trehalosi also consistently achieved a 3-log higher cell density compared to Mannhaemia 
haemolytica.  During co-culture Mannhaemia haemolytica growth was inhibited when 
Bibersteinia trehalosi entered the stationary phase (6 hours), resulting in a final cell 
density for Mannhaemia haemolytica that was 6-9 logs lower than expected with growth in 
the absence of Bibersteinia trehalosi.  When grown in co-culture, but separated by a 
membrane Bibersteinia trehalosi still was able to inhibit Mannhaemia haemolytica growth 
by a proximity dependent mechanism.  It was hypothesized that Bibersteinia trehalosi 
organisms overgrow Mannhaemia haemolytica organisms in pneumonic lung tissue of 
bighorn sheep due to their faster growth rate and higher final cell density in vitro.  This 
hypothesis was supported by unpublished data from a study by the same group 
demonstrating that Mannhaemia haemolytica can be detected by PCR from pneumonic 
lung tissue from bighorn sheep that were negative by traditional culture methods [45]. 
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Leukotoxin Analysis 
 Leukotoxin production has been associated with strains of both Bibersteinia 
trehalosi and Mannhaemia haemolytica and determined to be the most important virulence 
factor of the organisms [10].  The leukotoxin A gene encodes the protoxin which, after 
modification and secretion, targets and destroys ruminant lymphoid cells by binding to 
β(2) integrens.  A high concentration of leukotoxin A causes pore formation in lymphoid 
membranes while a low concentration induces apoptosis.  Sequencing based studies of the 
leukotoxin operon uncovered substantial levels of recombination and horizontal gene 
transfer among Mannhaemia haemolytica and Bibersteinia trehalosi isolated from 
domestic sheep and cattle [46].  Genetic sequencing of Mannhaemia haemolytica 
leukotoxin alleles demonstrates a higher diversity in sheep than in cattle suggesting that 
strain transmission from cattle to sheep is more common than from sheep to cattle [47].  
Bibersteinia trehalosi strains tend to be more host specific than strains of Mannhaemia 
haemolytica.  These findings may help explain why Bibersteinia trehalosi associated 
pneumonia is seen more in sheep than in cattle.  The results of sequencing studies have 
demonstrated that contrary to the hypothesis of “ubiquitous dispersal,” the relationship 
between bacterial phylogeny and geography suggest that there may be some 
phylogeographic patterning to Pasteurellaceae evolution [46]. 
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CHAPTER 3 
PATHOGENICITY OF BIBERSTEINIA TREHALOSI IN CALVES: RANDOMIZED 
CLINICAL TRIAL TO EVALUATE THE PATHOGENICITY OF BIBERSTEINIA 
TREHALOSI IN RESPIRATORY DISEASE AMONG CALVES 
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Abstract 
Introduction - Bibersteinia trehalosi causes respiratory disease in ruminants 
particularly in wild and domestic sheep. Recently, there has been an increased number of B. 
trehalosi isolates obtained from diagnostic samples from bovine respiratory disease cases. 
This study evaluated the role of B. trehalosi in bovine respiratory disease using an intra-
tracheal inoculation model in calves. 
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Objective – Determine if Bibersteinia trehalosi causes respiratory disease in cattle 
alone or in combination with Mannheimia haemolytica and if it can be recovered and 
cultured from lung tissue or lung wash. 
Animals – 35 cross bred dairy steers 
Procedures - Calves were inoculated intra-tracheally with either leukotoxin negative 
B. trehalosi, leukotoxin positive B. trehalosi, Mannheimia haemolytica, a combination of 
leukotoxin negative B. trehalosi and M. haemolytica, or negative control. Calves were 
euthanized and necropsy performed on day 10 of study. 
Results - B. trehalosi inoculated calves did not have increased lung involvement 
compared to control calves. Additionally, B. trehalosi was only cultured once from the 
lungs of inoculated calves at necropsy.  
Conclusions - Based on these findings B. trehalosi may not be a primary pathogen 
of respiratory disease in cattle. Culture of B. trehalosi from diagnostic submissions should 
not be immediately identified as a primary cause of respiratory disease.  
 
Background 
Bibersteinia trehalosi is a known pathogen of ruminants and has been identified 
worldwide [1]. B. trehalosi was formerly included in a single species of Pasteurella 
haemolytica as biotype T [2]. This pathogen was recently reclassified as B. trehalosi on the 
basis of phylogenetic studies [3]. B. trehalosi has been associated with systemic pasteurellosis 
or septicemia in lambs [4] and pneumonia in bighorn sheep (Ovis canadensis) [5, 6].  
Although B. trehalosi infections are considered rare in cattle, the agent is occasionally 
isolated from bovine lungs. Diagnostic reports of severe non-responsive Bovine Respiratory 
Disease (BRD) outbreaks associated with multi-drug resistant B. trehalosi have been 
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documented [7]. Clinical manifestations of these strains are often associated with multi-drug 
resistance and severe lung pathology. The reasons for development of these potentially highly 
virulent strains remain unclear. It has been hypothesized that B. trehalosi may have acquired 
increased pathogenicity from other bacteria. Some reports in the literature suggest that B. 
trehalosi and Mannheimia haemolytica can share genetic material [8, 9]. Earlier work has 
shown that nucleotide diversity of lktA from B. trehalosi is minimal (0.7 %) compared to M. 
haemolytica (22.0 %) and were genetically different from M. haemolytica [10]. This report 
included only B. trehalosi isolates from ovine samples. Bovine adapted isolates of B. trehalosi 
may have acquired some genetic material from M. haemolytica increasing its ability to infect 
cattle. 
Understanding the role different pathogens play in BRD is critical to understanding and 
effectively treating clinical cases. The primary objective of this study was to evaluate the 
pathogenicity of B. trehalosi in respiratory disease among calves using field strains of B. 
trehalosi.  
 
Materials and Methods  
Two B. trehalosi isolates were identified from diagnostic submissions of bovine 
cases for the challenge study. Isolate identification was confirmed by 16S ribosomal RNA 
analysis. One isolate was PCR positive for the leukotoxin (lktA) gene [11] and the other 
isolate was negative. The lktA gene was amplified with a 5’ primer lktA9 (5’-
TCAAGAAGAGCTGGCAAC-3’) and the 3’ primer lktA7 (5’-
AGTGAGGGCAACTAAACC-3’). Amplification parameters were: denaturation at 94°C 
for 45 s, annealing at 62°C for 45 s, and extension at 72°C for 2 min. The leukotoxin-PCR-
positive B. trehalosi isolate was cultured from the lungs, along with a Pasteurella 
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multocida, from a feedlot calf that had been treated with antibiotics multiple times for 
BRD that had fibrinosuppurative bronchopneumonia from a group of 273 kg Southeastern 
feedlot calves with 16% respiratory morbidity and 10% mortality. The leukotoxin-PCR-
negative B. trehalosi isolate was cultured from the brain of a bull with multifocal, 
suppurative meningoencephalitis.  
Thirty six 8-12 week old individually housed Holstein cross steer calves were 
obtained from a private calf raiser. Calves were tested for persistent infection by BVDV by 
immunohistochemistry prior to purchase and confirmed PI negative. Deep nasal swab 
samples were collected from each calf and submitted for bacterial culture to the diagnostic 
lab prior (Day -1) to inoculation. During the experimental challenge, calves were housed in 
a Biosecurity Level 2 facility at the Iowa State University Livestock Infectious Disease 
Isolation Facility. Each calf was confined separately in raised 0.9 x 1.8 meter pens that 
provided no opportunity for calf-to-calf contact in a room that held 12 calves at a time. 
Three groups of calves were utilized to accommodate room layout. Calves were provided 
free choice water and were fed mixed grass hay and a pre-mixed calf starter. Biosecurity 
procedures such as changing protective gloves and clothing between calves were employed 
by all research personnel working with calves. Calves were randomly assigned by a 
random number generator (www.Random.org) to one of five treatments.  Treatments were 
randomly assigned to 1 of 3 replicates (Table 1). Eight calves were assigned to each 
bacterial challenge treatment and 4 calves to a negative control treatment.  
The 5 treatment groups were: 
1) Negative control (Becton Dickinson BBL™ Brain Heart Infusion Broth 211059), 
2) Leukotoxin negative B. trehalosi, 
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3) Leukotoxin positive B. trehalosi, 
4) M. haemolytica 
5) Combination of leukotoxin negative B. trehalosi and M. haemolytica 
Prior to inoculation, each isolate was grown overnight on two blood agar plates and 
then transferred to Brain Heart Infusion broth immediately prior to inoculation to obtain an 
estimated 2.5 x 10
9
 CFU of bacteria per mL. Isolates for group 5 had an estimated 2.5 x 
10
9
 CFU of bacteria per mL for both leukotoxin negative B. trehalosi and M. haemolytica 
for a total of 5 x 10
9
 CFU of bacteria per mL. A small sample of the inoculum was 
enumerated on blood agar plates to determine exact concentration of the inoculum. 
Inoculums ranged on average from 1.7 x 10
9
 to 3.3 x 10
9
 CFU of bacteria per ml of broth. 
A sterile 90 cm number 8 French Foley catheter (MILA International) was used to 
inoculate each calf. The researcher administering the inoculum was masked to the 
treatment being administered. For each inoculation, a sterile catheter was passed intranasal 
to approximately the bifurcation of the trachea and 20 mL of the inoculum was infused. 
Following inoculation, the calf’s head was briefly elevated.  
Following inoculation, calves were monitored twice daily by trained personnel 
masked to treatment on days 1-10.  Measurements recorded included rectal temperature, 
pulse rate, and respiration rate.  Each calf was clinically assessed and assigned a 
respiratory and depression score during twice daily monitoring. The following scoring 
systems were used for the study.  
Respiratory Scores: 
0 – Normal, eyes are clear, nose is clean with no discharge, normal breathing 
1 – Mild Respiratory, serous discharge from eyes and\or nose, slight cough 
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2 – Moderate Respiratory, muco-purulent discharge, cough, increased respiratory rate 
3 – Severe Respiratory, excessive muco-purulent discharge, harsh cough, open mouth 
breathing 
Depression Scores: 
0 – Normal, calf is bright and alert, hold their head up and readily moves away from the 
observer 
1 – Mild depression, calf’s attitude is slightly depressed but responds quickly to observer 
and appears normal 
2 – Moderate depression, calf stands with head down, ears droop, abdomen lack of fill and 
may appear floppy, calf moves away slowly from observer 
3 – Severe depression, calf stands with head down and very reluctant to move, very 
noticeable gauntness of abdomen 
Any calf that was assigned a respiratory and/or depression score of three was 
considered a candidate for euthanasia. If calf was determined to be moribund from physical 
exam, it was humanely euthanized. All surviving calves were euthanized on day 10 of the 
study by use of captive bolt followed by a pithing rod. All euthanasias followed American 
Veterinary Medical Association guidelines [12]. 
Immediately following euthanasia, a necropsy was performed on each calf. The 
respiratory system was evaluated by a diagnostic pathologist. The percent abnormal lung 
was visually estimated for each lobe (Figure 1) and total lung involvement calculated as a 
percentage of total lung as described by Jericho and Langford [13]. Lungs and heart were 
removed from the calves and photographed (Figures 2-7).  Samples of representative lung 
as determined by the pathologist were submitted ISU Veterinary Diagnostic Laboratory for 
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routine culture and histology. For culture, samples were plated on bovine blood agar and 
incubated aerobically at 35°C, sheep blood agar and incubated anaerobically at 35°C, and 
tergitol-7 agar and incubated aerobically at 35°C. All samples were incubated overnight 
and suspect hemolytic and non-hemolytic colonies were selected for identification by 
matrix-assisted laser desorption/ionization--time of flight (MALDI-TOF) (Bruker).  
This protocol was approved by the Iowa State University Institutional Animal Care 
and Use Committee (#5-12-7352-B) and the Institutional Biosafety Committee (#12-I-
0017-A). Personnel conducting daily monitoring, the pathologist and the statistician were 
blinded to calves treatment group. 
 
Statistical Analysis 
Our goal was to describe the magnitude and variation of our collected 
measurements and assess the association of these variables with BRD and B. trehalosi. The 
primary outcomes of interest included percent lung involvement, temperature, depression 
score, and respiratory score. The percent abnormal lung response was analyzed using 
mixed effect Analysis of Variance (ANOVA) model, with Treatment as fixed effect and 
Group as a random effect. The remaining responses (Temperature, Depression score, and 
Respiratory score) were analyzed using a repeated measures ANOVA model, with 
Treatment, time and their interaction as fixed effects and group as a random effect. 
Comparisons among treatment groups were performed using Tukey's t-tests. SAS
®
 Version 
9.2 (SAS
®
 Institute Inc., Cary, NC, USA) was used in analyses. A p-value <0.05 was 
considered significant.  
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Results 
Thirty-five of the thirty-six candidates were enrolled in the study. One calf assigned 
to the M. haemolytica group died prior to enrollment in study. Pasteurella multocida was 
isolated from deep nasal swab samples from 34 of 35 calves. M. haemolytica was isolated 
from 8 of 35 calves. M. haemolytica positive nasal swab calves were fairly evenly spread 
across all five treatment groups (1/4 in Control group, 1/8 in Leukotoxin negative B. 
trehalosi group, 2/8 in Leukotoxin positive B. trehalosi group, 1/7 in M. haemolytica 
group, 3/8 in Leukotoxin negative B. trehalosi and M. haemolytica combination group). 
Six of the 35 enrolled calves were euthanized prior to day 10 of the study. Three of the 
euthanized calves (3/7) in the M. haemolytica group (days 2, 3 and 3) and three calves 
(3/8) in the leukotoxin negative B. trehalosi and M. haemolytica combination group (days 
3, 5, and 8) were euthanized according to protocol because of a clinical assessment of 
moribund. The mean estimated percent lung involvement was highest for the M. 
haemolytica group (49%) followed by the mixed infection of M. haemolytica and 
leukotoxin negative B. trehalosi (26%). The leukotoxin positive B. trehalosi group had a 
mean 18% estimated lung involvement while the leukotoxin negative B. trehalosi mean 
lung involvement was estimated to be 13%. The control group had a mean lung 
involvement estimate of 13% (Table 2). Calves with lung involvement had histologic 
lesions that were consistent with bronchointerstitial pneumonia (26 of 35 calves) and 20 of 
these calves also had evidence of pyogranulomatous pneumonia. 
M. haemolytica was isolated from 5 of 7 lungs of the M. haemolytica inoculated 
group and 4 of 8 lungs from the leukotoxin negative B. trehalosi and M. haemolytica 
combination group. B. trehalosi was isolated from one of 24 lungs that were inoculated 
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with B. trehalosi. Calf number 6 in the leukotoxin negative B. trehalosi and M. 
haemolytica combination inoculation treatment group was euthanized on day 3 of the study 
as reported above. The calf had 71.6% lung involvement and both M. haemolytica and a B. 
trehalosi were isolated from the lung tissue. B. trehalosi was not isolated from the lung 
tissue of any other calves that were inoculated with a B. trehalosi isolate. 
Rectal temperature (Figure 8), depression scores (Figure 9) and respiratory scores 
(Figure 10) followed an expected pattern after inoculation.  Rectal temperatures ranged 
from 35.3-41.3° C. Depression scores ranged from 0-3 and respiratory scores ranged from 
0-3.There were occasional time periods when differences in rectal temperatures, depression 
score or respiratory score between the M. haemolytica and the B. trehalosi or control 
groups were statistically significant (Figure 8, 9, and 10).  
The calves from both groups inoculated with B. trehalosi demonstrated increased 
rectal temperature (>39.5° C) at 7 hours after inoculation compared to calves that had been 
inoculated with M. haemolytica. Temperatures for the two B. trehalosi only treatment 
groups returned to normal levels (37.5 – 39.5° C) within 12 hours. Calves in the M. 
haemolytica only inoculation group did not demonstrate increased rectal temperatures 
(>39.5° C) on average until 24 hours following inoculation and temperatures of these 
calves remained elevated except for morning of day 2. Calves in the combined inoculation 
group fluctuated above and below 39.5° C throughout the study (Figure 8).  
Depression scores (Figure 9) for the M. haemolytica inoculation group began to 
increase 4 hours post inoculation and remained elevated at 1 or greater throughout the 
study. The combined inoculation group did not have increased depression scores (≥ 1) until 
day 4 of the study and never reached the severity of the M. haemolytica only inoculation 
37 
 
 
group. Neither of the B. trehalosi inoculation groups had elevated depression scores. The 
average depression score for the control group was 0.2.  Both B. trehalosi only inoculation 
groups had an average depression score of 0.3 while the M. haemolytica inoculation group 
had an average score of 1.3. The combined inoculation group had an average depression 
score of 0.6.  Respiratory scores for the M. haemolytica inoculation group ranged from 0-3 
and were not consistently abnormal (≥ 1) until day 4 of the study. None of the other groups 
had elevated average respiratory scores (Table 3). 
 
Discussion 
Results of this study indicate that the B. trehalosi isolates used in this study are not 
associated with significant disease in a research setting. Calves inoculated with either a 
leukotoxin positive (PCR positive for the leukotoxin (lktA) gene) or leukotoxin negative 
isolate of B. trehalosi did not demonstrate increased lung involvement compared to control 
calves. This finding contradicts some perceptions that B. trehalosi is an emerging primary 
respiratory pathogen of cattle [7]. In contrast, this study’s results are more supportive of B. 
trehalosi’s role in BRD as secondary and perhaps opportunistic bacteria. Reports of B. 
trehalosi associated pneumonia are from diagnostic submissions, often without access to 
history of inciting causes of respiratory disease, nutritional health of calves, additional 
stressors or information on antimicrobial therapies. In this challenge model healthy calves 
were challenged with field isolates of B. trehalosi and extensive lung involvement was not 
identified post inoculation.  
The limitations of this study include the small size of the study, isolate credibility, 
the inoculation method and the health status of the calves prior to inoculation. The study 
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was designed as a pilot study to evaluate the pathogenicity of B. trehalosi in cattle. The 
number of calves in each group was limited as much as possible to decrease the number of 
calves sacrificed while still providing important information. The small size of the study 
decreases the statistical power to identify statically significant differences even though 
numerically the difference between the negative control group (inoculated with broth only) 
and the positive control group (M. haemolytica) were substantial.  
The authors are unaware of any B. trehalosi isolates that have demonstrated 
pathogenicity in a challenge model in cattle. The B. trehalosi isolates selected for this 
study originated from field submissions to a diagnostic laboratory. Our approach was to 
use leukotoxin positive and negative B. trehalosi isolates that had been associated with 
respiratory disease and could potentially be associated with lung pathology in the study 
calves.  
Though unlikely, it is possible that, during the inoculation procedure, the dose was 
inadvertently misplaced into the esophagus instead of the lungs. There are multiple bovine 
respiratory disease challenge models cited in the literature including trans-tracheal 
injection, trans-thoracic injection, bronchoscope assisted, and using a nasal-tracheal 
approach that this study utilized. Confirmation that the catheter was correctly placed in the 
trachea as opposed to the esophagus can be difficult. However, the M. haemolytica positive 
control group, had substantial lung involvement and a p-value of 0.07 compared to the 
negative control group suggesting that the inoculation technique and the challenge model 
was valid. 
Calves in the study were conventionally reared dairy crossbred calves. Calves were 
purchased from a calf raiser and were considered clinically normal at the time of purchase 
39 
 
 
and did not exhibit signs of respiratory disease at enrollment. However, two calves in the 
control group had lung lesions (20-26 % lung involvement). Thus, this pathology was 
presumed to have resulted from a previous infection not associated with inoculation. 
Evidence of lung pathology from prior respiratory disease in some control calves may 
confound results between treatment groups. Histologic lesions characteristic of a previous 
BRSV infection were seen in 17 of the calves. Since two control calves demonstrated some 
lung pathology, the potential difference between treatment groups and the control group 
was affected.   
Pre-study pharyngeal swabs did not identify any calves carrying B. trehalosi and 
the calf farm did not have a history of B. trehalosi disease. Despite this, it is still possible 
that calves could have had exposure to B. trehalosi prior to enrollment in the project. 
Given the age of the calves, it is also possible that passive immunity played a role in 
immune response.  There is currently not a validated serologic test for cattle to determine 
previous exposure to B. trehalosi.  It is possible that calves may have had previous 
unknown exposure to B. trehalosi that enhanced their immunological response.  
It was surprising that calves inoculated with a combination of M. haemolytica and 
B. trehalosi tended to have numerically less lung involvement than that of M. haemolytica 
inoculation alone (difference was not significant). One would expect that mixed infections 
would potentiate increased lung involvement and subsequent pathology. Other research has 
suggested that B. trehalosi can inhibit the growth of M. haemolytica. Dassanayake et al. 
[14] reported that B. trehalosi inhibited the growth of M. haemolytica in co-culture when 
B. trehalosi enters the stationary phase. One possible explanation for this finding is that; 
when both bacteria are inoculated simultaneously, B. trehalosi may inhibit in vivo growth 
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of M. haemolytica until the immune system removes B. trehalosi.  This postulated in vivo 
inhibition may delay the onset of clinical signs of BRD (such as a temperature spike and 
decrease the subsequent severity of lung involvement). 
Our goal was to determine if B. trehalosi is really an emerging primary BRD 
pathogen as has been reported or if infection occurs secondary to some other viral/bacterial 
insult. Cortese et al. 2012 reported peracute fatal pneumonia in healthy adult cattle 
attributed to B. trehalosi. Other anecdotal reports concerning B. trehalosi and BRD suggest 
that B. trehalosi is associated with severe fibrinous pneumonia with consolidation 
(especially caudal lobes) and pleuritis that is unresponsive to antimicrobial therapy. The 
more minor role that B. trehalosi may play in BRD is supported by the isolation results 
described in this study. B. trehalosi was isolated from only one set of lungs post 
inoculation and in that case the sample was obtained only 3 days following inoculation 
from a calf that had been inoculated with both B. trehalosi and M. haemolytica. This 
finding suggests that B. trehalosi may not persist long term in the bovine lung. The 
temperature response of calves inoculated with B. trehalosi or M. haemolytica was 
different (p<0.05) over time. The early spike and rapid return to normal in rectal 
temperature from the B. trehalosi inoculated calves may indicate that the immune system 
in the lungs may more rapidly identifies and responds to a B. trehalosi bacterial insult 
compared to the M. haemolytica inoculated calves. The authors acknowledge that B. 
trehalosi isolates have been obtained from samples submitted from field cases. These 
“positives” suggest the occurrence of an opportunistic infection and proliferation of B. 
trehalosi after normal lung defenses have been compromised by other primary respiratory 
pathogens. The plausibility of B. trehalosi as a secondary, even an opportunistic pathogen 
41 
 
 
is a stronger argument than B. trehalosi as an emerging primary BRD pathogen of 
economic importance. 
 
Conclusion 
This pilot study suggests that B. trehalosi may not be an important primary 
pathogen of respiratory disease in cattle. The study’s results suggest that B. trehalosi is a 
secondary, or perhaps opportunistic, BRD pathogen. Culture of this bacterium from 
diagnostic submissions should not necessarily be interpreted or cited as a primary cause of 
respiratory disease but may still have a role as a secondary pathogen or an opportunistic 
invader. Clinicians and diagnosticians should temper a B. trehalosi culture in context of the 
clinical setting. Practically, identification of B. trehalosi as the primary isolate from a 
submitted lung sample may suggest a failure in identification or treatment of a major BRD 
pathogen such as M. haemolytica. Further challenge studies designed to assess B. 
trehalosi’s interaction with other BRD pathogens (IBR, BVDV, Mycoplasma bovis, 
Histophilus somni) should be conducted. Additionally, a challenge model designed to 
evaluate if B. trehalosi, inoculated after M. haemolytica has already initiated lung damage, 
can lead to more severe BRD would be beneficial. 
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Tables and Figures 
Table 1. Replicate and Treatment Group Assignments 
Assignment of calves to treatment groups by replicate of study presented in table format. 
Replicate and Treatment Group Assignments 
 
Replicate 1 Replicate 2 Replicate 3 
Control Calves 1 1 2 
Leukotoxin negative B. 
trehalosi 
3 3 2 
Leukotoxin postive B. trehalosi 3 3 2 
M. haemolytica 3 2 3 
M. haemolytica and leukotoxin 
negative B. trehalosi 
2 3 3 
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Table 2. Percent Lung Involvement by Treatment Group 
Individual and mean lung involved in disease process as a percentage of total lung volume. 
Treatment group means that were statistically different from other treatment groups are 
indicated by different letters (a or b) in table. Adjusted p-values of treatment group from 
control group is reported. 
Percent Lung Involvement by Treatment Group 
 Control Leukotoxin 
negative B. 
trehalosi 
Leukotoxin 
positive B. 
trehalosi 
M. 
haemolytica 
M. 
haemolytica 
and 
leukotoxin 
negative B. 
trehalosi 
Calves 20.4 0 36.55 57.25 71.6 
 26.2 24.25 27.1 53.95 61.3 
 0 21.7 28.1 26 62.85 
 4.4 32.1 27.1 33.15 0 
  18.05 14.2 28.6 1.8 
  6.15 1.5 63.6 0.6 
  3.6 11.35 75.1 4.75 
  0 1.45  6.1 
Mean * 12.75 a 13.2 a 18.4 a 48.2 b 26.1 a, b 
Adj P 
value ** 
 0.9999 0.9981 0.0715 0.8049 
*means with different letters are statistically different (p<0.05) 
**Adjusted p value of treatment from the control group 
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Table 3. Average Depression and Respiratory Score by Treatment Group 
Average depression and respiratory scores over the course of the study are reported for 
each treatment group in table format.  
Average Depression and Respiratory Score by Treatment Group 
 Average Peak Depression 
Score (Range) 
Average Peak 
Respiratory Score 
(Range) 
Control 0.25 (0-1) 1 (1-1) 
Leukotoxin negative B. trehalosi 0.75 (0-2) 1 (0-1) 
Leukotoxin postive B. trehalosi 1 (0-2) 1.25 (1-2) 
M. haemolytica 2 (0-3) 1.7 (1-3) 
M. haemolytica and leukotoxin 
negative B. trehalosi 
1.25 (0-3) 1.25 (0-3) 
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Figure 1. Necropsy form 
Form used to score percent lung involvement by lobe 
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Figures 2 and 3. Mannheimia haemolytica inoculated lung demonstrating cranioventral 
consolidation 
      
 
Figure 4 and 5. Bibersteinia trehalosi leukotoxin positive inoculated lung demonstrating a 
smaller percentage of cranioventral consolidation 
     
Figures 6 and 7. BHI broth inoculated lung demonstrating normal lung tissue 
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Figure 8. Temperature Over Time by Treatment Group 
Line graph of rectal temperature by treatment group for each time point when temperature 
was recorded. Time points that were statistically different are indicated by different letters 
(a or b).  
Temperature Over Time by Treatment Group 
 
Points with different letters are statistically different (p<0.05) 
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Figure 9. Depression Score Over Time by Treatment Group 
Line graph of depression score by treatment group for each time point when depression 
score was recorded. Time points that were statistically different are indicated by different 
letters (a or b).  
Depression Score Over Time by Treatment Group 
 
Points with different letters are statistically different (p<0.05) 
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Figure 10. Respiratory Score Over Time by Treatment Group 
Line graph of respiratory score by treatment group for each time point when respiratory 
score was recorded. Time points that were statistically different are indicated by different 
letters (a or b).  
Respiratory Score Over Time by Treatment Group 
 
Points with different letters are statistically different (p<0.05) 
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CHAPTER 4 
SERUM CONCENTRATIONS OF HAPTOGLOBIN AND HAPTOGLOBIN-MATRIX 
METALLOPROTEINASE 9 (Hp-MMP 9) COMPLEXES OF BOVINE CALVES IN A 
BACTERIAL RESPIRATORY CHALLENGE MODEL 
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Abstract 
Objective— Evaluate potential diagnostic applications of serum Hp and Hp-MMP 
9 concentrations in calves with BRD and establish a timeline for their detection in calves 
experimentally challenged with Bibersteinia trehalosi and Mannheimia haemolytica. 
Animals— 35 cross bred dairy calves 
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Procedures— Calves were inoculated via tracheal catheterization with either a PCR 
confirmed leukotoxin negative B. trehalosi isolate, a PCR confirmed leukotoxin positive B. 
trehalosi isolate, a Mannheimia haemolytica isolate, a combination of leukotoxin negative 
B. trehalosi and M. haemolytica, or a negative control. Serum samples were collected 
throughout the study.  Calves were euthanized and necropsy performed on day 10 post 
inoculation.  
Results— M. haemolytica inoculated calves had increased lung involvement.  
Serum Hp and Hp- MMP 9 concentrations were elevated compared to the other treatment 
groups.  Increases in serum Hp and Hp-MMP 9 concentrations for the M. haemolytica 
group were significantly different from other study groups on day 7 of the study.  B. 
trehalosi inoculated calves did not have increased lung involvement compared to control 
calves, but the leukotoxin positive B. trehalosi group demonstrated increased serum Hp-
MMP 9 concentrations from day 3 to the end of the study compared to the pre-inoculation 
concentrations.  
Conclusions and Clinical Relevance— Serum Hp-MMP 9 concentration is a useful 
diagnostic tool for detecting early pulmonary inflammation in calves challenged with B. 
trehalosi and M. haemolytica.  Serum Hp-MMP 9 may also be a useful tool in detecting 
subclinical pulmonary inflammation in challenged calves. 
 
Introduction 
Bovine respiratory disease (BRD) has been shown to affect various biomarkers in 
cattle [1-7].  Two biomarkers that have been identified for diagnostic potential are serum 
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haptoglobin (Hp), matrix metalloproteinase 9 (MMP 9), and the complexes that they are 
able to form (Hp-MMP 9) [1, 6-9].   
Free Hp is an alpha-2 globulin that is primarily synthesized in the liver [3].  Free 
Hp’s primary function is to bind to free hemoglobin in the blood.  By scavenging the free 
hemoglobin, Hp helps to prevent oxidative tissue damage and conserve iron by returning 
the heme residue to the host’s metabolic process.  This scavenging mechanism also serves 
to decrease the risk of free hemoglobin being utilized for bacterial pathogen growth [7, 8]. 
MMP 9 is a collagenase belonging to the gelatinase B group [5].  The gelatinase B 
group is a family of MMP’s that are zinc dependent proteinases capable of degrading at 
least one component of the extracellular matrix or basement membrane.  This capability 
assists in the migration of white blood cells, mostly neutrophils, from the blood to the site 
of inflammation [4].  MMP 9 is stored in tertiary granules within the bovine neutrophils 
and is released when neutrophil degranulation is induced by either chemical or microbial 
stimuli [1, 5, 10, 11].  After release, MMP 9 is able to cleave interleukin 8, if present in the 
microenvironment into active interleukin 8.  This creates a positive feedback loop for 
neutrophil migration [10].  While only neutrophils have been demonstrated to store MMP 
9 for immediate release [8], other cells such as alveolar macrophages can be induced to 
produce MMP 9 [5, 12]. 
Free Hp and MMP 9 are secreted by multiple cellular sources in response to a 
variety of challenges; Hp-MMP 9 complexes have been shown to form exclusively in 
neutrophils [1].  These complexes are stored until neutrophil degranulation at which time 
they are released [1, 6, 8].  Hp has been demonstrated to have a high diagnostic sensitivity 
for detecting infectious or inflammatory conditions.  Due to its poor specificity, it cannot 
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be used as the primary diagnostic test for any one condition.  Free Hp is also poor at 
differentiating between acute and chronic inflammation [1, 7].  Free MMP 9 is more 
specific to acute inflammation, but it is not specific enough to differentiate between 
healthy and diseased cattle [1, 4].  Hp-MMP 9 complexes are capable of differentiating 
between acute and chronic inflammation as their release from neutrophils is associated 
with acute inflammatory responses [1, 8]. 
Various biomarkers potentially associated with BRD have been studied.  In 
previous studies Hp was demonstrated to increase after calves were exposed to 
Mannheimia haemolytica via intra-tracheal inoculation with the earliest detection 
occurring at 24 hours, and peak concentrations occurring at 3 days post inoculation [6, 7].  
In another challenge study, increases in serum Hp concentrations in calves infected with 
BVDV were not detected until 7-9 days post infection [7].  The purpose of this study was 
two-fold: to evaluate the diagnostic applications of serum Hp-MMP 9 concentrations in 
calves with BRD and to establish a timeline for their detection in calves undergoing 
experimental challenge with Bibersteinia trehalosi and Mannheimia haemolytica. 
 
Materials and methods  
Prior to initiating the study, the protocol was approved by the Iowa State University 
Institutional Animal Care and Use Committee (IACUC 8-11-7187-B) and the Institutional 
Biosafety Committee (IBC#11-D-0017-A). This study is a hypothesis generating study 
representing a secondary use of calves enrolled in a challenge study designed to evaluate 
the pathogenicity of Bibersteinia trehalosi in respiratory disease among bovine calves [13]. 
The rationale for the secondary use of these calves to meet additional objectives is 
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consistent with using the 3R principles to maximize information obtained from animal 
research [14].   
Calves were inoculated via tracheal catheterization with either a PCR confirmed 
leukotoxin negative B. trehalosi isolate, a PCR confirmed leukotoxin positive B. trehalosi 
isolate, a Mannheimia haemolytica isolate, a combination of leukotoxin negative B. 
trehalosi and M. haemolytica, or a negative control as previously described [13]. 
Blood samples were collected from each calf via jugular venipuncture on Days 1 
(pre-inoculation), 3, 5, 7, 9, and 10 (immediately prior to euthanasia).  Blood samples were 
centrifuged at 4000 rpm for 15 minutes.  Following centrifugation, samples were placed on 
ice before being transferred, using a transfer pipette, to an appropriately labeled cryovial.  
Boxes containing cryovials were placed immediately in an ultra-low freezer and stored at - 
70°C until being shipped to The Ohio State University on dry ice for analysis.   
All surviving calves were euthanized on day 10 of the study, necropsied, and 
evaluated for percent abnormal lung involvement as previously described [13]. 
 
Serum Haptoglobin-Matrix metalloproteinase 9 (Hp-MMP 9) ELISA assay 
The ELISA for heteromeric serum complexes of bovine Hp-MMP 9 was performed 
as described previously with minor alterations [1, 6, 15].  The ELISA is designed to 
capture bovine MMP 9 and detect haptoglobin bound to immobilized MMP 9.  Un-
conjugated antibodies prepared against purified bovine MMP 9 (MAb 10.1; in 100 µL, 2 
µg antibody per well in 0.1 M sodium carbonate (pH 9.6), was allowed to bind to the wells 
of 96 well ELISA plates overnight at 4°C.  After capture antibody binding, the plates were 
washed with 50 mM Tris buffered saline (TBS; pH 7.5) containing 0.05% tween 20, 5 
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times.  After washing, the wells were tapped on dry paper towels and the wells were 
individually coated with 300 μL of SuperBlock T20 (TBS) (ThermoScientific, Cat #37536) 
at 4° C for 120 minutes to prevent non-specific protein binding.  After blocking, the wells 
were again washed with 50 mM Tris buffered saline (TBS) containing 0.05% tween 20 and 
100 μL of serum standards and unknown serum samples from experimental calves were 
added and incubated on a plate shaker (120 min at 21°C).  The serum samples were each 
diluted 1:100 with sample diluent (TBS + 1% Bovine serum albumin + 0.05% Tween 20).  
Standards consisted of serial dilutions of serum from a cow possessing a concentration of 
912.6 ng heteromeric complexes of Hp-MMP 9 complex/mL and were created by diluting 
serum in sample diluent (TBS + 1% Bovine serum albumin + 0.05% Tween 20).  Standard 
concentrations ranged from 3.56 - 228 ng/mL. These standard concentrations represent the 
upper and lower limits of quantitation respectively.  After analyte binding, standard and 
sample wells were vigorously washed 5 times with TBS+0.05% Tween 20.  After washing, 
a rabbit anti-bovine Hp-horseradish peroxidase (HRP) conjugate was added as a detection 
antibody (1:5,000; secondary antibody 100 µL, containing 0.02 µg per well in TBS + 0.1% 
BSA; Immunology Consultants laboratory RHPT-10P; HRP conjugate, 1 mg/mL) [1].  The 
unbound HRP conjugate was removed by repeated washing (as above), after which 100 µL 
of TMB (SureBlue reserve TMB microwell peroxidase substrate; Kirkegaard-Perry Labs, 
Cat# 53-00-01) was added to each well to detect bound Hp-MMP 9.  The wells were 
incubated for 20 minutes at 22
o
C and the reaction stopped by addition of 100 uL of 0.1N 
hydrochloric acid.  The concentrations of Hp-MMP 9 were determined using the linear 
portion of the equation of the line described by absorbance of the calibrators at 450 nm and 
the known concentration of these calibrators.  Any sample remaining outside of the range 
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of the standard curve (> 228 ng/mL) were diluted further and re-analyzed.  Linear 
regression analysis of the serum standard concentration versus absorbance curves on each 
plate was created to determine the serum concentrations of heteromeric Hp-MMP 9 
complexes in the experimental calves.  Concentrations determined from the slope and 
intercept of the standard curve were corrected for dilution (x 100) and reported in ng/mL.  
The between plate variability in calibrators was 3% (range 0.98-2.7%) and the average 
coefficient of correlation of the calibration curves for this assay is 0.91 (range 0.85-0.91) 
 
Serum total haptoglobin ELISA assay 
Serum Hp concentrations were determined as described (Bovine haptoglobin 96-
well ELISA, Life Diagnostics, West Chester, PA 19380) using commercial Bovine 
haptoglobin ELISA test kits, according to manufacturer’s instructions.  Standard curves 
were prepared using purified bovine haptoglobin standard (2.5 μg/mL) included with the 
kit at a concentration range from 7.8 – 250 ng/mL.  Serum samples were diluted according 
to the kit instructions (1:2,000 dilution) and were run in duplicate.  Controls included were 
normal bovine serum, 5% BSA in TBS and blank wells. Linear regression of the Hp 
calibrator concentration versus absorbance was used to determine the equation for the line.  
The slope and intercept of this line was used to calculate the concentration of serum total 
Hp in the unknown animal samples.  These concentrations were corrected for the dilution 
factor (x 2,000) and the concentrations reported in μg/mL. 
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Statistical analysis  
Hp- MMP 9 and Hp were analyzed by repeated measures analysis of variance 
(ANOVA), with treatment, time, and their interaction as fixed effects and animal as subject 
of repeated measures.  Lung involvement was analyzed by analysis of variance model, 
with treatment as explanatory variable.  Correlations were calculated among the values of 
lung involvement, Hp, and Hp-MMP 9 for both Hp and Hp-MMP 9 serum concentrations 
as both ranked and absolute values prior to the challenge as well as averaged over the time 
of the study.  SAS® Version 9.2 (SAS® Institute Inc., Cary, NC, USA) was used in 
analyses. A p-value <0.05 was considered significant. 
 
Results and Discussion  
Lung involvement 
Prior to inoculation all calves appeared clinically normal.  Pasteurella multocida 
was isolated from pharyngeal swab samples from 34 of 35 calves.  M. haemolytica was 
isolated from 8 of 35 calves.  M. haemolytica positive pharyngeal swab calves were spread 
across all five treatment groups (1/4 in control group, 1/8 in leukotoxin negative B. 
trehalosi group, 2/8 in leukotoxin positive B. trehalosi group, 1/7 in M. haemolytica group, 
3/8 in leukotoxin negative B. trehalosi and M. haemolytica combination group).   
Six of the 35 enrolled calves were euthanized prior to day 10 of the study.  Three 
calves (3/7) from the M. haemolytica group (days 2, 3 and 3) and three calves (3/8) from 
the leukotoxin negative B. trehalosi and M. haemolytica combination treatment (days 3, 5 
and 8) were euthanized according to protocol because of a clinical assessment of 
moribund.   
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The mean estimated percent lung involvement was highest for the M. haemolytica 
group (49%).  The mixed infection group of leukotoxin negative B. trehalosi and M. 
haemolytica had a mean lung involvement of 26%.  The leukotoxin positive B. trehalosi 
had a mean lung involvement of 18% while the leukotoxin negative B. trehalosi mean lung 
involvement was estimated to be 13%. The control group had a mean lung involvement 
estimate of 13%.  There was evidence of a statistically significant (p=0.018) difference for 
mean percent total lung involvement between the M. haemolytica group and the leukotoxin 
negative B. trehalosi group.  There were no significant differences between the other 
treatment groups.  Even though the control group had a lower mean percent lung 
involvement than the leukotoxin negative B. trehalosi treatment group, the low number of 
study subjects in the group did not lend sufficient power to the group mean to make it 
significantly different from the M. haemolytica treatment group.  The mean and median 
values were similar in all treatment groups except the mixed infection group.  This group 
had a high amount of variability within it as evidenced by a mean percent lung 
involvement of 26% and a median percent lung involvement of 5%.  The high variability 
made drawing conclusions difficult in this group (Figure 1).  
 
 Free Hp 
Other studies have found that serum Hp is nearly undetectable in healthy cattle [8].  
Concentrations up to about 200 μg/mL are considered acceptable for healthy animals [2, 7, 
9, 16].  Concentrations between about 200 and 400 μg/mL are associated with mild 
inflammation and concentrations greater than about 400 μg/mL suggest severe 
60 
 
 
inflammation [7].  Serum Hp concentration does not differ with age or sex in cattle [2, 7, 
9].   
In this study, 11 calves (2/4 in the control group, 2/8 in the leukotoxin negative B. 
trehalosi group, 4/8 in the leukotoxin positive B. trehalosi group, 1/7 in the M. 
haemolytica group, and 2/8 in the leukotoxin negative B. trehalosi and M. haemolytica 
combination group) had serum Hp concentrations greater than 200 μg/mL prior to 
inoculation.  Two of the calves had low serum concentrations of Hp-MMP 9 indicating the 
presence of chronic inflammation.  M. haemolytica was cultured from the pharyngeal of 
both calves.  Nine of the calves with high serum concentrations of Hp also had high serum 
concentrations of Hp-MMP 9 indicating the presence of chronic inflammation which was 
associated with an acute inflammatory event.  Three of these calves were culture positive 
for M. haemolytica from pharyngeal swabs.  Nineteen calves had no detectible serum Hp 
prior to inoculation.   
The interaction between treatment group and bleeding date was a statistically 
significant effect (p=0.01).  The mean serum Hp concentration for the leukotoxin positive 
B. trehalosi treatment group was significantly (p=0.008) different from the other treatment 
groups for the pre-inoculation bleeding date, indicating that more calves with evidence of 
chronic inflammation prior to commencement of the study were randomly assigned to this 
treatment group.  On the fourth and sixth bleeding dates (days 7 and 10) there was a 
significant (p<0.05) difference in the mean Hp concentration between the M. haemolytica 
treatment group and the leukotoxin negative B. trehalosi treatment group and the 
leukotoxin negative B. trehalosi and M. haemolytica combination group.  The M. 
haemolytica treatment group demonstrated significant elevations in serum Hp 
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concentrations from the first two bleeding dates to the third bleeding date (day 5) (p=0.02).  
The elevation in serum Hp concentration remained significant (p<0.02) throughout the 
study.  This finding is in agreement with other studies that have demonstrated an increase 
in serum Hp after M. haemolytica infection [4, 6].  Concentrations in this study peaked on 
day 7 rather than day 3 as previously reported.  A decrease in the serum Hp concentration 
for the mixed infection group can be observed between the second and third bleeding dates 
(days 3 and 5).  This observation supports findings by Dassanayake et al. suggesting that 
B. trehalosi is capable of inhibiting the growth of M. haemolytica in vivo [17].  In this 
study the difference in serum Hp concentration is not significantly different from the other 
treatment groups.  Two calves from this treatment group were euthanized before the third 
bleeding time point.  The smaller treatment group likely did not have enough power for a 
statistical difference to be observed (Figure 2).    
 
Hp-MMP 9 
The mean serum Hp-MMP 9 concentration for all treatment groups prior to 
inoculation was 104 ng/mL, with a minimum value of 0 ng/mL, a maximum value of 752.2 
ng/mL, and a median value of 4.15 ng/mL.  Little to no Hp-MMP 9 should be detectible in 
the serum of healthy calves [6].  Sixteen calves had no detectible serum Hp-MMP 9 
concentration prior to inoculation.  For this study a serum concentration greater than 
20ng/mL was considered high.  Thirteen calves had high serum Hp-MMP 9 concentrations 
prior to inoculation.  Four of the thirteen calves had low serum concentrations of Hp, 
suggesting the presence of a mild acute inflammatory process.  None of these 4 calves 
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were culture positive for M. haemolytica from the pharyngeal swabs.  Nine of the thirteen 
calves had high serum concentrations of Hp and were discussed previously.   
Treatment group, bleeding date, and their interaction were all significant (p<0.01) 
effects.  On the fourth bleeding date (day 7) the mean serum Hp-MMP 9 concentration for 
the M. haemolytica group became significantly different from the negative control, the 
leukotoxin negative B. trehalosi, and the leukotoxin negative B. trehalosi and M. 
haemolytica combination groups (p=0.01, p=0.009, and p=0.004 respectively).  This 
difference continued throughout the study.  On the fifth bleeding date (day 9) the mean 
serum Hp-MMP 9 concentration for the M. haemolytica group became significantly 
different from the leukotoxin positive B. trehalosi group (p=0.006) and remained different 
throughout the rest of the study.  The M. haemolytica group demonstrated significant 
elevations in serum Hp-MMP 9 concentrations from the first three bleeding dates to the 
last three bleeding dates (p<0.02).  The leukotoxin positive B. trehalosi treatment group 
demonstrated a small but significant (p<0.004) elevation in serum Hp-MMP 9 
concentrations from the pre-inoculation bleeding date to the second bleeding date (day 3) 
that continued throughout the study (Figure 3).  This finding is consistent with other 
studies that have demonstrated the rapid recruitment and accumulation of neutrophils at the 
onset of BRD [6] as well as the action of leukotoxins to stimulate the active degranulation 
of bovine neutrophils [5]. 
 
Correlations 
There was statistically significant (p<0.0001) evidence of a strong (r=0.7) 
correlation between Hp and Hp-MMP 9 serum concentrations as both ranked and absolute 
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values prior to inoculation.  Evidence of a relationship remained statistically significant 
over time (p<0.0001), but the strength of the relationship varied depending on if a Pearson 
(absolute values) or Spearman (ranked data) correlation coefficient was calculated.  The 
Pearson correlation coefficient was r=0.63; whereas, the Spearman correlation coefficient 
was r=0.79.  This strong relationship was expected since both substances have been 
established as biomarkers for inflammation and the test for free Hp measures Hp-MMP 9 
contribution also. 
There was statistically significant evidence (p<0.05) of a moderate correlation 
(r=0.44 and r=0.35) that became stronger over time (r=0.67 and r=0.48) between Hp-MMP 
9 and percent lung involvement for both ranked and absolute values respectively.   
There was statistically significant evidence (p=0.04) of a moderate (r=0.35) correlation 
between free Hp and percent lung involvement for ranked, but not absolute values prior to 
inoculation.  This correlation became stronger (r=0.54, p=0.0008) when values were 
averaged over the time of the study.  The correlation between free Hp and percent lung 
involvement for absolute data was also statistically significant when averaged over time 
(r=0.41, p=0.015).   
This correlation data indicates that Hp-MMP 9 serum concentrations may be a 
good ante-mortem diagnostic indicator of lung damage that is found at the time of the 
calf’s death.  This data also supports the conclusion from other studies that Hp-MMP 9 
serum concentration is a better diagnostic test for lung damage than free Hp serum 
concentration [1].  Future studies should be conducted to determine reference ranges of 
serum Hp-MMP 9 for different levels of disease severity.  
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Conclusion 
All study calves appeared to be clinically normal prior to inoculation in this study.  
Culture results of pharyngeal swabs taken from calves prior to inoculation showed that all 
but one calf was positive for P. multocida.  The presence of this bacterium did not appear 
to have an impact on pre-inoculation values of serum Hp or Hp-MMP 9 since many of the 
calves had serum concentrations of these two biomarkers that were within limits 
considered acceptable for healthy animals [2, 7, 9, 16].  The pharyngeal swabs for 8 calves 
were culture positive for M. haemolytica prior to inoculation.  This finding could have 
potentially affected the development of lung lesions as well as increases in serum Hp and 
Hp-MMP 9 concentrations in calves that were members of treatment groups other than the 
M. haemolytica group.  The effect was not large enough to preclude seeing statistically 
significant results from the challenge in the M. haemolytica group.  The development of a 
rapid, inexpensive test for serum Hp-MMP 9 concentrations could have clinical 
applications as a screening test for subject enrollment in BRD studies.  Subjects with 
elevated serum concentrations could be excluded from participation.   
Significant differences were observed between the M. haemolytica group and the 
other treatment groups in percent total lung involvement, serum Hp, and serum Hp-MMP 9 
concentrations.  The difference in percent total lung involvement demonstrates that the 
inoculation technique was appropriate for this challenge model.  The increase in serum Hp 
and Hp-MMP 9 concentrations at day 7 are consistent with other reports of these two 
biomarkers having diagnostic potential with respect to BRD.  Results suggest a different, 
slightly later, timeframe for using them as diagnostic tools. 
No significant difference was observed between the leukotoxin positive B. trehalosi 
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treatment group and the negative control, leukotoxin negative B. trehalosi, and 
combination of leukotoxin negative B. trehalosi and M. haemolytica groups with respect to 
percentage of total lung involvement or serum Hp concentrations.  A small but significant 
increase was noted in the serum Hp-MMP 9 concentrations of the leukotoxin positive B. 
trehalosi treatment group from day 1 to day 3, indicating that serum Hp-MMP 9 
concentrations may be a more sensitive test for pulmonary inflammation than visible lung 
damage or serum Hp concentrations.  This finding also provides evidence that the 
leukotoxin positive strain of B. trehalosi induced more neutrophil degranulation leading to 
a higher release of Hp-MMP 9 complexes than the leukotoxin negative strain of B. 
trehalosi.  In this study the earlier rise in the serum Hp-MMP 9 concentration for the 
leukotoxin positive B. trehalosi treatment group than for the M. haemolytica treatment 
group may indicate that bovine neutrophils respond faster to a B. trehalosi infection than to 
a M. haemolytica infection. 
The stronger significant correlation between serum Hp-MMP 9 concentration and 
percent lung involvement than between serum Hp concentration and percent lung 
involvement support the conclusions of other studies that serum Hp-MMP 9 concentrations 
can be an effective tool for early diagnosis of BRD [6] and that it is a better diagnostic tool 
for acute inflammation than serum Hp [1].  Future studies to determine a reference range 
for serum Hp-MMP 9 concentration and to develop a rapid, inexpensive test would help to 
make serum Hp-MMP 9 concentration a clinically useful diagnostic tool.  
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Figures  
Figure 1. Distribution of percent lung involvement by treatment group 
Treatment group 0: Negative control group, Treatment group 1: leukotoxin negative B. 
trehalosi group, Treatment group 2: leukotoxin positive B. trehalosi group, Treatment 
group 3: M. haemolytica group, Treatment group 4: Combination of leukotoxin negative B. 
trehalosi and M. haemolytica group  
Means with different letters are significantly different (p<0.05) 
Diamonds represent the group mean.  Boxes represent the middle two quartiles of 
individual values, divided by the center line which represents the median.  Bars adjacent to 
the boxes represent the outer two quartiles of individual values. 
Distribution of percent lung involvement by treatment group 
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Figure 2. Serum Hp concentration in micrograms/mL over time by treatment group 
Treatment group 0: Negative control group, Treatment group 1: leukotoxin negative B. 
trehalosi group, Treatment group 2: leukotoxin positive B. trehalosi group, Treatment 
group 3: M. haemolytica group, Treatment group 4: Combination of leukotoxin negative B. 
trehalosi and M. haemolytica group  
Circles above trend lines indicate significant differences from other treatment groups.  
Triangles below trend lines indicate significant differences from prior bleeding dates. 
Serum Hp concentration over time by treatment group 
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Figure 3. Serum Hp-MMP 9 concentration in nanograms/mL over time by treatment group 
Treatment group 0: Negative control group, Treatment group 1: leukotoxin negative B. 
trehalosi group, Treatment group 2: leukotoxin positive B. trehalosi group, Treatment 
group 3: M. haemolytica group, Treatment group 4: Combination of leukotoxin negative B. 
trehalosi and M. haemolytica group  
Circles above trend lines indicate significant differences from other treatment groups.  
Triangles below trend lines indicate significant differences from prior bleeding dates. 
Serum Hp-MMP 9 concentration over time by treatment group 
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CHAPTER 5 
GENERAL CONCLUSIONS 
 
Conclusions 
 During identification and selection of Bibersteinia trehalosi isolates to be used as 
challenge strains, it was determined that bacterial identification using 16S ribosomal RNA 
gene sequencing and matrix-assisted laser desorption/ionization--time of flight (MALDI-
TOF) was faster and more accurate than identification using traditional bench top 
metabolism based methods.  This finding for cattle strains of B. trehalosi is in agreement 
with the finding of Miller et al.  According to Miller et al., metabolism based methods of 
identifying members of the Pasteurellacea family lack sufficient accuracy and resolution 
for reliably discerning bacterial causes of respiratory disease in bighorn sheep.  He 
suggested that metabolism based methods should be augmented by molecular techniques 
for phylogenetic analysis [1].  Based on experience in this study, the researchers would 
suggest replacing metabolism based identification methods with molecular identification 
methods for faster and more accurate bacterial identification. 
 Conflicting reports exist describing the prevalence of B. trehalosi in the 
nasopharynx of healthy cattle.  Some reports describe the organism as an ubiquitous 
commensal organism [2, 3].  Others report that the organism is not readily isolated from 
healthy, unstressed cattle [4].  B. trehalosi was not isolated from the nasopharynx of any of 
the study subjects prior to inoculation.  This finding supports the position that the organism 
is not readily isolated from healthy, unstressed cattle.  However, the study calves were 
obtained from a single source, thus limiting the scope of inference. 
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 No published reports exist describing the prevalence of Pasteurella multocida in 
the nasopharynx of cattle in the United States.  One report from the United Kingdom 
reported a prevalence of 17% of P. multocida in the nasopharynx of suckling age beef and 
dairy calves in Scotland [5].  P. multocida was isolated from 34/35 calves prior to 
inoculation in this study.  The prevalence rate for this group of calves of 97% was much 
higher than previously reported.  The high prevalence rate observed in this group of calves 
may be a true reflection of the prevalence rate of conventionally reared dairy calves in the 
United States compared to Scotland.  Alternatively, the prevalence rate may be artificially 
inflated in this group of calves due to previous viral challenges on the farm of origin.  The 
cause of the observed high prevalence rate was outside the scope of this study.  A study to 
determine an accurate prevalence rate of various bacterial organisms in the nasopharynx of 
young bovine calves would be justified.  
 No significant differences were found between the groups of calves challenged 
with B. trehalosi alone or in conjunction with M. haemolytica and the calves inoculated 
with BHI broth with respect to percent lung involvement, rectal temperature, respiratory or 
depression score, or serum Hp or Hp-MMP 9 concentration in this study.  During the 
challenge study, measured parameters from the groups of calves inoculated with B. 
trehalosi were more similar to the measured parameters from the negative control group 
which was inoculated with brain heart infusion (BHI) broth than to the positive control 
group which was inoculated with a virulent strain of Mannheimia haemolytica.   
 Significant differences in percent lung involvement, rectal temperatures, depression 
and respiratory scores, and Hp and Hp-MMP 9 serum concentrations did exist between the 
groups of calves challenged with B. trehalosi alone or in conjunction with M. haemolytica 
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and the calves inoculated with M. haemolytica alone.  Percent lung involvement for the M. 
haemolytica challenged group of calves was significantly higher when compared to the 
other study groups.  Rectal temperatures for calves in the B. trehalosi groups peaked at 7 
hours post inoculation then decreased to within normal range.  Rectal temperatures for 
calves in the M. haemolytica group did not peak until 24 hours post inoculation and 
remained elevated throughout the rest of the study.  Depression and respiratory scores were 
significantly higher for the calves in the M. haemolytica group than for the calves in the B. 
trehalosi groups from days 5 and 7 to the end of the study respectively.  Serum 
concentrations of Hp and Hp-MMP 9 were significantly higher for the calves in the M. 
haemolytica group than for the calves in the other groups from day 7 to the end of the 
study.  The faster peak in rectal temperature and rise in serum concentrations of Hp and 
Hp-MMP 9 may indicate that the immune system in the lungs may more rapidly identify 
and respond to a B. trehalosi bacterial insult compared to a M. haemolytica insult in 
inoculated calves. 
 Dassanayake et al. has reported studies suggesting that leukotoxin is the most 
important virulence factor of B. trehalosi and M. haemolytica [6].  In the challenge study 
calves in the group inoculated with leukotoxin positive B. trehalosi and in the group 
inoculated with M. haemolytica demonstrated significant increases in serum concentrations 
of Hp-MMP 9 when compared to pre-inoculation concentrations.  The increase occurred at 
day 3 for the calves in the leukotoxin positive B. trehalosi group and at day 7 for the calves 
in the M. haemolytica group.  Several conclusions can be drawn from this observation.  
Our findings support those of Dassanayake et al. [6] that the ability of an organism to 
produce leukotoxin is an important virulence factor.  Serum concentrations of Hp-MMP 9 
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appear to be a more sensitive diagnostic test for acute inflammation in calves with bacterial 
respiratory disease than serum concentrations of Hp.  The faster rise in serum 
concentrations of Hp-MMP 9 for calves challenged with leukotoxin positive B. trehalosi 
than for calves challenged with M. haemolytica also supports our finding that the immune 
system in the calves’ lungs may more rapidly identify and respond to the leukotoxin insult 
from B. trehalosi compared to M. haemolytica.   
 Dassanayake et al. has also demonstrated the ability of B. trehalosi to inhibit the 
growth of M. haemolytica in vitro and has suggested that the same inhibition may occur in 
vivo in bighorn sheep [7].  The lack of a significant difference between the group of calves 
inoculated with a combination of B. trehalosi and M. haemolytica and the group of calves 
inoculated with BHI broth with respect to percent lung involvement, rectal temperature, 
respiratory or depression score, and serum Hp or Hp-MMP 9 concentration supports the 
hypothesis that the inhibition occurs in vivo in cattle as well. 
 In our study B. trehalosi was not isolated from the lung of inoculated calves after 
day 3 post inoculation.  This suggests that by itself B. trehalosi does not persist long term 
in the bovine lung.  In field cases where it is cultured from pneumonic bovine lung, it is 
biologically plausible that B. trehalosi is a secondary invader that has overgrown M. 
haemolytica which was responsible for the primary lung damage. 
 In conclusion, this study’s results suggest that B. trehalosi may not be an important 
primary pathogen of respiratory disease in cattle. It is likely a secondary, or opportunistic, 
BRD pathogen. Culture of this organism from diagnostic submissions should not 
necessarily be interpreted or cited as a primary cause of respiratory disease but may still 
have a role as a secondary pathogen or an opportunistic invader.  Based on the results of 
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this study, B. trehalosi may be a component of BRDC, but it should not be considered a 
sufficient cause of BRDC in cattle.   
 
Suggestions for Future Research 
 It may be prudent to repeat this challenge model using different strains of B. 
trehalosi as more research is reported and understanding increased about the importance of 
an organism’s ability to produce leukotoxin and other potential virulence factors.  
Endoscope assisted inoculation may also remove potential differences in diagnostic results 
from misplaced inoculum.  Future studies should also consider the interaction of B. 
trehalosi with other bovine respiratory pathogens. 
 If serum concentrations of Hp-MMP 9 are to be used commercially as an ante-
mortem diagnostic test for BRD a rapid, economical test will need to be developed and a 
reference range for healthy cattle established.  
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